Share price · LKFT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LKFT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 15 Sep 2026+4.5%
- 12 Aug 2026-2.8%
- 11 Aug 2026+6.8%
- 23 Jul 2026-2.3%
Nothing announced by LKFT that day or the session before.
- 11 May 2026-4.0%
Nothing announced by LKFT that day or the session before.
- 8 May 2026+3.1%
Nothing announced by LKFT that day or the session before.
- 24 Mar 2026-6.6%
Share of unusual movement by asset
For each asset, the share of LKFT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 46% |
| Sessions with no dated event | — | 54% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | BCMA x CD3Multispecific antibody | Multiple Myeloma |
Discontinued programmes (4)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (2)
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2030 (1)
May 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $35M | $3.4B | — | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $153M | $304M | $3.6B | $283M | report ↗ |
| 2025-Q1 | $79M | $192M | $3.6B | $161M | report ↗ |
| 2024-H1 | $152M | $157M | $3.7B | — | report ↗ |
| 2024-Q1 | $68M | $78M | $3.8B | — | report ↗ |
| 2023-H1 | $355M | $229M | $4.2B | — | report ↗ |
| 2023-Q1 | $192M | $111M | $4.4B | — | report ↗ |
| 2022-H1 | $300M | $273M | $4.6B | $35M | report ↗ |
| 2022-Q1 | $153M | $112M | $5.2B | $15M | report ↗ |
| 2021-H1 | $334M | $324M | $6.0B | $66M | report ↗ |
| 2021-Q1 | $150M | $157M | $6.0B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.3B | $521M | $3.5B | $214M | report ↗ |
For fiscal year 2025, Lakefront Biotherapeutics NV reported revenue of $1,260.73M, up 322.7% YoY, and R&D spend of $520.75M, up 43.4% YoY. Cash and equivalents were $3,524.63M, net income was $363.73M, and quarterly net burn was $214.35M.
Insider transactions
This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 89 reporting institutions held 31.3M shares ($935.1M, 47.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 16,707,477 | $501.2M |
| 2 | TANG CAPITAL MANAGEMENT LLC | 3,785,991 | $113.6M |
| 3 | Madison Avenue Partners, LP | 2,465,179 | $74.0M |
| 4 | EcoR1 Capital, LLC | 1,667,119 | $50.0M |
| 5 | Prosight Management, LP | 1,550,000 | $46.5M |
| 6 | AMERIPRISE FINANCIAL INC | 1,424,674 | $42.7M |
| 7 | DME Capital Management, LP | 482,746 | $14.5M |
| 8 | SEGALL BRYANT & HAMILL, LLC | 426,412 | $12.8M |
| 9 | Point72 Asset Management, L.P. | 332,125 | $10.0M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 315,400 | $9.5M |
| 11 | BlackRock, Inc. | 312,106 | $9.4M |
| 12 | D. E. Shaw & Co., Inc. | 215,718 | $6.5M |
| 13 | UBS Group AG | 175,289 | $5.3M |
| 14 | DAFNA Capital Management LLC | 130,175 | $3.9M |
| 15 | CITADEL ADVISORS LLC | 124,428 | $3.7M |